Overview of Causality Assessment in Drug-Induced Liver Injury
|
|
- Allen Perkins
- 5 years ago
- Views:
Transcription
1 REVIEW Overview of Causality Assessment in Drug-Induced Liver Injury Paul H. Hayashi, M.D., M.P.H. The diagnosis of drug-induced (or herbal/dietary supplement induced) liver injury (DILI) remains largely a diagnosis of exclusion. Research into diagnostic serum markers has made great progress, but few markers have made it into clinical use. For now, two diagnostic methods are in widest use: the Roussel Uclaf Causality Assessment Model (RUCAM) and expert consensus opinion. 1,2 Only the former is available to the clinician. Both methods have obvious weaknesses, and developing a better diagnostic is a clear mandate. ROUSSEL UCLAF CAUSALITY ASSESSMENT MODEL The RUCAM is an algorithmic scorecard published in 1993 to clinically diagnose DILI. Eight experts from six countries subjectively built the algorithm (Table 1) based on published literature. The clinician first decides whether the injury is hepatocellular or mixed/cholestatic. By convention this decision is based on the r value: alanine aminotransferase/upper limit of normal (ULN) 4 alkaline phosphatase/uln. The r values > 5 are hepatocellular, 2 to 5 are mixed, and <2 are cholestatic. Thereafter, seven criteria are scored. First and most important is time to onset, or latency, which categorizes time from start, or end, of drug exposure to onset of hepatotoxicity. Next, the course of reaction, or washout, is scored, with more rapid decline in liver enzymes garnering more points. The RUCAM scores each suspected agent. So the fourth criteria addresses cases with more than one agent implicated, penalizing if other suspicious agents weigh in against the agent being scored. The non-drug-related causes criteria give or take points depending on the thoroughness of excluding non-dili diagnoses. Next, previous information on hepatotoxicity for a particular agent is assessed, giving more points for drugs more likely to cause liver injury. Finally, response to readministration is scored, although such rechallenge is rare. All scores are totaled with sums falling into subjective categories of likelihood (Table 2). Although straightforward in principle, RUCAM scoring instructions are ambiguous. For example, should the r Abbreviations: AP, alkaline phosphatase; DILI, drug-induced (or herbal/dietary supplement induced) liver injury; DILIN, Drug- Induced Liver Injury Network; RUCAM, Roussel Uclaf Causality Assessment Model; ULN, upper limit of normal. From the Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, NC. Potential conflict of interest: Nothing to report. Received 27 November 2016; accepted 3 January 2017 View this article online at wileyonlinelibrary.com VC 2017 by the American Association for the Study of Liver Diseases 29 CLINICAL LIVER DISEASE, VOL 9, NO 2, FEBRUARY 2017 An Official Learning Resource of AASLD
2 TABLE 1. ROUSSEL UCLAF CAUSALITY ASSESSMENT MODEL Criteria Hepatocellular Cholestatic or Mixed 1. Time to onset Initial Exposure Subsequent Exposure Points Initial Exposure Subsequent Exposure Points Timing from: 5-90 da da da da. 12 Drug start <5, > 90 da. >15 da. 11 <5, > 90 da. >90 da. 11 Drug stop 15 da. 15 da da. 30 da Course Difference between peak alanine aminotransferase and ULN value Difference between peak alkaline phosphatase (or bili) and ULN After drug cessation Decrease 50% in 8 da. 13 Decrease 50% in 180 da. 12 Decrease 50% in 30 da. 12 Decrease < 50% in 180 da. 11 Decrease 50% in > 30 da. 0 Persistence or increase or no info 0 Decrease < 50% in > 30 da Risk factors Ethanol/pregnancy Ethanol: yes 11 Ethanol or pregnancy: yes 11 Ethanol: no 0 Ethanol or pregnancy: no 0 Age (years) <55 0 < Other drugs None or no info 0 None or no info 0 Drug with suggestive timing 21 Drug with suggestive timing 21 Known hepatotoxin with suggestive timing 22 Known hepatotoxin with suggestive timing 22 Drug with other evidence for a role (e.g., 1 rechallenge) 23 Drug with other evidence for a role (e.g., 1 rechallenge) Competing causes All of group I* and II ruled out 12 All of group I* and II ruled out 12 All of group I ruled out 11 All of group I ruled out 11 4 to 5 of group I ruled out 0 4 to 5 of group I ruled out 0 <4 of group I ruled out 22 <4 of group I ruled out 22 Nondrug cause highly probable 23 Nondrug cause highly probable Previous information Reaction in product label 12 Reaction in product label 12 on hepatotoxici- ty of the drug Reaction published; no label 11 Reaction published; no label 11 Reaction unknown 0 Reaction unknown 0 7. Response to repeat Positive 13 Positive 13 administration Compatible 11 Compatible 11 Negative 22 Negative 22 Not done or not interpretable 0 Not done or not interpretable 0 *Group I: hepatitis A virus, hepatitis B virus, hepatitis C virus (acute), biliary obstruction, alcoholism, and recent hypotension (shock liver). Group II: cytomegalovirus, Epstein-Barr virus, and herpes virus infection. Adapted with permission from Journal of Clinical Epidemiology. 1 Copyright 1993, Elsevier. value be calculated at onset or at peak level of enzyme elevation? For latency, should the time from drug start, or drug stop, or both be scored? The terms alcohol exposure and known hepatotoxin are not clearly defined. These ambiguities lead to RUCAM s poor interuse and intrauser reliability in exact score agreement. 3 However, agreement on the five categories of likelihood is better. Validation using published rechallenge cases was done, but legitimacy of using such cases for validation is unclear. 4,5 Nevertheless, RUCAM remains a valuable tool for the clinician by providing a starting point for evaluating DILI. It highlights areas of diagnostic importance and requires the precise delineation of latency and course 30 CLINICAL LIVER DISEASE, VOL 9, NO 2, FEBRUARY 2017 An Official Learning Resource of AASLD
3 that is so critical in diagnosis. Also, RUCAM s positive predictive value for discerning at least probable DILI compared with expert opinion (described next) is excellent at 95%. 6 Negative predictive value is poor at 23%. Thus, RUCAM is good at identifying DILI, but poor at ruling it out. TABLE 2. RUCAM SUM SCORE CATEGORIES OF LIKELIHOOD Category RUCAM Sum Score Highly probable >8 Probable 6 to 8 Possible 3 to 5 Unlikely 1 to 3 Excluded <1 EXPERT CONSENSUS OPINION Partly because of RUCAM s shortcomings, the US Drug-Induced Liver Injury Network (DILIN) developed a consensus expert opinion process to support a registry of well-vetted DILI cases (Fig. 1). Although unavailable to the clinician, it is arguably the best way of identifying DILI cases for clinical and bench research. The DILIN has included six to eight centers over more than a decade. The investigators at each site enroll cases and gather clinical data and blood samples for 6 months. All the data are submitted to a central coordinating center that then generates a standardized narrative and summary form that includes tables of laboratory values, concomitant medications, and clinical history. These are distributed electronically to three DILIN investigators, one from the enrolling site and two chosen at random from other sites. Each reviewer has 2 weeks to independently assign FIG 1 Diagram of DILIN expert consensus opinion process. (A) Enrollment and data gathering occur through the enrolling medical center. (B) Six months of data are collated and put into standardized forms at the data coordinating center. Forms released to three assigned DILIN investigators by secure Web site. (C) Three investigators have 2 to 3 weeks to independently assess the case. In this example, two reviewers assign the case a 2 (highly likely DILI), but one reviewer considers it a 3 (possible DILI). (D) Four days of discussion ensues, which may include all DILIN investigators. (E) If agreement is reached by , the case is closed and logged. (F) If no agreement is reached, the case is formally presented and discussed by teleconference among all DILIN investigators to reach resolution. 31 CLINICAL LIVER DISEASE, VOL 9, NO 2, FEBRUARY 2017 An Official Learning Resource of AASLD
4 TABLE 3. DILIN EXPERT CONSENSUS OPINION SCORES, CORRESPONDING SUBJECTIVE LIKELIHOODS, AND DESCRIPTIONS Score Category Likelihood Description 1 Definite >95% Beyond reasonable doubt 2 Highly likely 75% to 95% Clear and convincing, but less than definitive 3 Probable 50% to 75% Preponderance of evidence support 4 Possible 25% to 49% Not supported by preponderance of evidence but cannot exclude 5 Unlikely <25% Highly unlikely based on evidence a subjective score from 1 to 5, each score corresponding to a percentage likelihood range (Table 3). Each implicated agent is similarly scored. One Monday a month, case data, reviewers, and scores are released to all DILIN investigators for 4 days of discussion. If consensus is reached by , the case is closed and recorded. If consensus cannot be reached, a teleconference occurs that Thursday for formal case presentation and discussion. If necessary, a vote is taken to resolve persistent disagreements: one vote per center and majority prevails. Individual expert opinion has poor interrater reliability, but the DILIN s consensus protocol improves retest reliability substantially. 7 However, there are no validity data for this process, and most of all, it is cumbersome, expensive, and not available to the clinician. TOWARD A BETTER DIAGNOSTIC INSTRUMENT Operational ambiguity for the RUCAM and inaccessibility for expert opinion summarize each method s major shortcomings. Going forward, two approaches are being taken. First, the RUCAM provides a good foundation to support a long overdue update by experts in the field. Unlike RUCAM s originators, we now have mature registries of well-documented cases that can inform decisions on which criteria to keep and how to better weight the scores. Also, the ambiguities can be clarified, leading to wider acceptance and reliability. Keeping with RUCAM s original purpose, a revision should provide a clinician-friendly tool for all suspected DILI cases. Second, the DILIN s robust database offers the opportunity to allow the computer to lead the way. Rather than staying within a set framework of subjective parameters, the computer can determine the most important criteria and weighting by sophisticated modeling. Preliminary efforts suggest that such modeling may be best at making separate tools for particular medications with well-known injury patterns (e.g., isoniazid). 8 SUMMARY The RUCAM remains the best diagnostic tool available to the clinician. It provides a solid framework that reminds clinicians of necessary diagnostic information. Compared with expert opinion, it can identify DILI very well, but cannot rule it out. The DILIN s expert consensus opinion remains a research tool, but may be the turnkey toward better diagnostic methods by providing valid and robustly documented cases for analyses. Indeed, growing registries of cases across the globe create an opportunity and mandate to move forward by either building on the current RUCAM or developing a computer-driven instrument de novo. 9,10 CORRESPONDENCE Paul H. Hayashi, M.D., M.P.H., UNC Liver Center, Division of Gastroenterology and Hepatology, CB# 7584 Burnett-Womack Building, Room 8011, Chapel Hill, NC paul_hayashi@med.unc.edu REFERENCES 1) Danan G, Benichou C. Causality assessment of adverse reactions to drugs---i. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46: ) Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, et al; DILIN Study Group. et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009;32: ) Rochon J, Protiva P, Seeff LB, Fontana RJ, Liangpunsakul S, Watkins PB, et al; Drug-Induced Liver Injury Network (DILIN). Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology 2008;48: ) Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs---ii. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993;46: CLINICAL LIVER DISEASE, VOL 9, NO 2, FEBRUARY 2017 An Official Learning Resource of AASLD
5 5) Hayashi PH. Causality assessment in drug-induced liver injury. Semin Liver Dis 2009;29: ) Rockey DC, Seeff LB, Freston J, Chalasani N, Bonacini M, Fontana RJ, et al. Comparison between expert opinion and RUCAM for assignment of causality in drug-induced liver injury. Gastroenterology 2007;132:A ) Hayashi PH, Barnhart HX, Fontana RJ, Chalasani N, Davern TJ, Talwalkar JA, et al. Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN). Liver Int 2015;35: ) Tillmann H, Barnhart H, Serrano J, Rockey DC. A novel computerized drug induced liver injury causaltiy assessment tool (DILI-CAT). Hepatology 2016;64(1 suppl):320a. 9) Bjornsson ES, Ekbom A. Scandinavian epidemiological research in gastroenterology and hepatology. Scand J Gastroenterol 2015;50: ) Bessone F, Hernandez N, Lucena MI, Andrade RJ; Latin Dili Network Latindilin and Spanish Dili Registry. The Latin American DILI Registry experience: a successful ongoing collaborative strategic initiative. Int J Mol Sci 2016;17: CLINICAL LIVER DISEASE, VOL 9, NO 2, FEBRUARY 2017 An Official Learning Resource of AASLD
Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN)
Liver International ISSN 1478-3223 DRUG-INDUCED LIVER INJURY Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN)
More informationChronic Liver Disease after Acute Hepatocellular DILI
Chronic Liver Disease after Acute Hepatocellular DILI Robert J. Fontana, MD University of Michigan Medical Center DILI Natural history of acute DILI Transplant/ death Chronic DILI Chronic DILI Incidence
More informationDiagnostic evaluation of suspected Drug-Induced Liver Injury
Diagnostic evaluation of suspected Drug-Induced Liver Injury Ynto de Boer, MD Department of Gastroenterology and Hepatology Disclosure No disclosures Drug-induced liver injury? Outline What is DILI? What,
More informationDrug-induced liver injury due to varenicline: a case report
Sprague and Bambha BMC Gastroenterology 2012, 12:65 CASE REPORT Drug-induced liver injury due to varenicline: a case report David Sprague 1 and Kiran Bambha 2* Open Access Abstract Background: Liver injury
More informationAbstract AIM: To analyze the clinical features of druginduced liver injury (DILI), and discuss the risk factors affecting its prognosis.
: http://www.baishideng.com/wcjd/ch/index.aspx : http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.11569/wcjd.v24.i8.1257 2016 3 18 ; 24(8): 1257-1263 ISSN 1009-3079 (print) ISSN 2219-2859 (online) 2016
More informationThe HMG-CoA reductase inhibitors (statins) are. Spectrum of Statin Hepatotoxicity: Experience of the Drug-Induced Liver Injury Network
Spectrum of Statin Hepatotoxicity: Experience of the Drug-Induced Liver Injury Network Mark W. Russo, 1 Jay H. Hoofnagle, 2 Jiezhun Gu, 3 Robert J. Fontana, 4 Huiman Barnhart, 3 David E. Kleiner, 5 Naga
More informationShould There Be a Standard of Care (SOC) for Drug-Induced Liver Injury (DILI)? Leonard B Seeff, MD
Should There Be a Standard of Care (SOC) for Drug-Induced Liver Injury (DILI)? Leonard B Seeff, MD Drug-Induced Liver Injury: Are We Ready to Look? March 23-24,2011 AASLD, FDA/CDER, PhRMA A Common Statement
More informationDrug induced liver injury: accuracy of diagnosis in published reports
248 Teschke R, et al., 2014; 13 (2): 248-255 ORIGINAL ARTICLE March-April, Vol. 13 No. 2, 2014: 248-255 Drug induced liver injury: accuracy of diagnosis in published reports Rolf Teschke,* Christian Frenzel,**
More informationDrug-, herb- and dietary supplement-induced liver injury
Special article Arch Argent Pediatr 2017;115(6):e397-e403 / e397 Drug-, herb- and dietary supplement-induced liver injury María L. Cavalieri, M.D. a and Daniel D Agostino, M.D. a a. Department of Pediatric
More informationDrug-Induced Liver Injury Network Causality Assessment: Criteria and Experience in the United States
International Journal of Molecular Sciences Review Drug-Induced Liver Injury Network Causality Assessment: Criteria and Experience in the United States Paul H. Hayashi University of North Carolina Liver
More informationHHS Public Access Author manuscript Hepatology. Author manuscript; available in PMC 2017 March 01.
Febuxostat-Induced Acute Liver Injury Matt Bohm, DO, Raj Vuppalanchi, MD, Naga Chalasani, MD, and Drug Induced Liver Injury Network (DILIN) Department of Medicine, Indiana University School of Medicine,
More informationLeonard B. Seeff, MD Hepatology Consultant, Retired
Leonard B. Seeff, MD Hepatology Consultant, Retired Subjects with Active Liver Disease Need Special Observation Leonard B. Seeff, MD Hepatology Consultant, Retired DILI Conference XIV 19-20 March 2014
More informationLeonard B. Seeff, M.D. Consultant Einstein Healthcare Network. Click to view Biosketch and Presentation Abstract or page down to review presentation
Leonard B. Seeff, M.D. Consultant Einstein Healthcare Network Click to view Biosketch and Presentation Abstract or page down to review presentation ALT as a Biomarker for Drug-Induced Liver Injury Leonard
More informationDrug Induced Liver Injury: A Clinical Perspective. Robert J. Fontana, MD
Drug Induced Liver Injury: A Clinical Perspective Robert J. Fontana, MD Drug induced liver injury (DILI) is an uncommon cause of acute and chronic liver injury of increasing importance to patients, clinicians,
More informationFlavocoxid is a proprietary blend of purified, plantderived
Annals of Internal Medicine Original Research Acute Liver Injury due to Flavocoxid (Limbrel), a Medical Food for Osteoarthritis A Case Series Naga Chalasani, MD; Raj Vuppalanchi, MD; Victor Navarro, MD;
More informationDrug-induced liver injury (DILI) is an important
Hepatic Histological Findings in Suspected Drug-Induced Liver Injury: Systematic Evaluation and Clinical Associations David E. Kleiner, 1 Naga P. Chalasani, 2 William M. Lee, 3 Robert J. Fontana, 4 Herbert
More informationWoman, 35, With Jaundice and Altered Mental Status Lauren Kemph, NP
Woman, 35, With Jaundice and Altered Mental Status Lauren Kemph, NP IN THIS ARTICLE Results of case patient s initial laboratory work-up, page 39 Top 10 prescription medications associated with idiosyncratic
More informationEvaluation of prognostic markers in severe drug-induced liver disease
PO Box 2345, Beijing 100023, China World J Gastroenterol 2007 January 28; 13(4): 628-632 World Journal of Gastroenterology ISSN 1007-9327 wjg@wjgnet.com 2007 The WJG Press. All rights reserved. RAPID COMMUNICATION
More informationDrug Induced Liver Injury at a Tertiary Hospital in India: Etiology, Clinical Features and Predictors of Mortality
442 ORIGINAL ARTICLE May-June, Vol. 16 No. 3, 2017: 442-450 The Official Journal of the Mexican Association of Hepatology, the Latin-American Association for Study of the Liver and the Canadian Association
More informationA Drug-Induced Liver Injury by Western Medication
대한한방내과학회지제 36 권 1 호 (2015 년 3 월 ) J. Int. Korean Med. 2015:36(1)69-75 A Drug-Induced Liver Injury by Western Medication Chang-gue Son Liver and Immunology Research Center, Oriental Medical College in Dae-Jeon
More informationManagement of Patients with Past or Present Hepatic Abnormalities
S21 Management of Patients with Past or Present Hepatic Abnormalities Evidence Based Medicine Official recommendations Expert opinion Course of action before tocilizumab therapy in patients with a history
More informationJay H. Hoofnagle, M.D. Director, Liver Disease Research Branch Division of Digestive Diseases and Nutrition National Institute of Diabetes and
Jay H. Hoofnagle, M.D. Director, Liver Disease Research Branch Division of Digestive Diseases and Nutrition National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health,
More informationVIRAL HEPATITIS. Definitions. Acute Liver Disease (Hepatitis A &E, Alcoholic hepatitis, DILI and ALF) Acute Viral Hepatitis Symptoms
Acute Liver Disease (Hepatitis A &E, Alcoholic hepatitis, DILI and ALF) Definitions AST and ALT Markers of hepatocellular injury Ryan M. Ford, MD Assistant Professor of Medicine Director of Viral Hepatitis
More informationHBV Forum 2 April 18 th 2017 Hilton Amsterdam.
HBV Forum 2 April 18 th 2017 Hilton Amsterdam www.forumresearch.org Detection, Assessment and Management of DILI During Drug Development for HBV: The IQ DILI Initiative. Arie Regev, MD Global Patient Safety
More informationHHS Public Access Author manuscript Gastroenterology. Author manuscript; available in PMC 2016 June 01.
Features and Outcomes of 899 Patients with Drug-induced Liver Injury: The DILIN Prospective Study N Chalasani 1, HL Bonkovsky 2, R Fontana 3, W Lee 4, A Stolz 5, J Talwalkar 6, KR Reddy 7, PB Watkins 8,
More informationA Severe Hepatotoxicity by Antituberculosis Drug, and its Recovery in Oriental Hospital
J Korean Med. 2016;37(2):119-124 pissn 1010-0695 eissn 2288-3339 Case Report A Severe Hepatotoxicity by Antituberculosis Drug, and its Recovery in Oriental Hospital Chang-Gue Son Liver and Immunology Research
More informationClick to view Biosketch and Presentation Abstract or page down to review presentation
Alexander Gerbes, MD Professor of Internal Medicine, Medizinische Klinik und Poliklinik II Klinikum der Universität München, FRG Andreas Benesic, MD Physician, Researcher Medizinische Klinik und Poliklinik
More informationDrug Induced Liver Injury (DILI)
Drug Induced Liver Injury (DILI) Aisling Considine- Consultant Hepatology Pharmacist. King s College Hospital NHS Foundation Trust aislingconsidine@nhs.net Drug Induced Liver Injury /Disease Acute Liver
More informationDrug Induced Liver Injury Associated with Daptomycin: A Case Report and Cohort
AAC Accepts, published online ahead of print on 12 May 2014 Antimicrob. Agents Chemother. doi:10.1128/aac.03157-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 Drug Induced
More informationPaul B. Watkins 1 James H. Lewis. Jaime D. Blais 5 Dan M. Smotzer. Vicente E. Torres 6 Frank S. Czerwiec
Drug Saf (2015) 38:1103 1113 DOI 10.1007/s40264-015-0327-3 ORIGINAL RESEARCH ARTICLE Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease:
More informationA Case of Cold Medicine-Induced Hepatitis Treated with Herbal Medicine
2011. Vol.32. No.6. 112-116 The Journal of Korean Oriental Medicine Case Report A Case of Cold Medicine-Induced Hepatitis Treated with Herbal Medicine Chang-Gue Son Liver and Immunology Research Center,
More informationCase Report Metronidazole Induced Liver Injury: A Rare Immune Mediated Drug Reaction
Volume 2013, Article ID 568193, 4 pages http://dx.doi.org/10.1155/2013/568193 Case Report Metronidazole Induced Liver Injury: A Rare Immune Mediated Drug Reaction Dayakar Kancherla, 1 Mahesh Gajendran,
More informationDrug-induced liver injury
Drug-induced liver injury Vincent Wong MBChB(Hons), MD, FRCP, FHKCP, FHKAM Professor, Department of Medicine and Therapeutics Director, Cheng Suen Man Shook Foundation Centre for Hepatitis Studies Deputy
More informationThe Burden of Drug Induced Liver Injury
The Burden of Drug Induced Liver Injury Victor J. Navarro, MD Chairman, Division of Hepatology Einstein Healthcare Network Professor of Medicine Jefferson Medical College Philadelphia, PA, USA Victor J.
More informationTopic review - A patient with impaired liver function. Dr. Karen Hin Kwan Luk 18/1/2018
Topic review - A patient with impaired liver function Dr. Karen Hin Kwan Luk 18/1/2018 Case M/69 PMH: 1. Diabetes 2. Hypertension 3. Hyperlipidaemia 4. Paroxysmal supraventricular tachycardia 5. Cerebral
More informationEVALUATION OF ABNORMAL LIVER TESTS
EVALUATION OF ABNORMAL LIVER TESTS MIA MANABAT DO PGY6 MOA 119 TH ANNUAL SPRING SCIENTIFIC CONVENTION MAY 19, 2018 EVALUATION OF ABNORMAL LIVER TESTS Review of liver enzymes vs liver function tests Clinical
More informationRoxanne Lim, Hassan Choudry, Kim Conner, and Wikrom Karnsakul. Correspondence should be addressed to Wikrom Karnsakul;
Case Reports in Pediatrics, Article ID 156389, 7 pages http://dx.doi.org/10.1155/2014/156389 Case Report A Challenge for Diagnosing Acute Liver Injury with Concomitant/Sequential Exposure to Multiple Drugs:
More informationAnzaroot; astragalus sarcocolla dymock; hepatic encephalopathy; acute hepatitis; hepatic injury; roussel UCLAF causality assessment scale
Open Journal of Clinical & Medical Case Reports Volume 3 (2017) Issue 21 ISSN 2379-1039 Anzaroot (Astragalus sarcocolla dymock) is associated with Acute hepatitis and hepatic encephalopathy in children
More informationHepatotoxicity due to Isoniazide in a Patient with Crohn s Disease: Case Report and Literature Review
Case report Hepatotoxicity due to Isoniazide in a Patient with Crohn s Disease: Case Report and Literature Review Gustavo Adolfo Reyes M., MD, 1 Germán David Carvajal P., MD, 2 Mónica Lorena Tapias M.,
More informationDrug-induced liver injury 2017: the diagnosis is not easy but always to keep in mind
European Review for Medical and Pharmacological Sciences 2017; 21 (1 Suppl): 122-134 Drug-induced liver injury 2017: the diagnosis is not easy but always to keep in mind G. MARRONE 1, F.G. VACCARO 1, M.
More informationDoc, is it good for my liver?
Victor J. Navarro, MD, FAASLD Herbal and Dietary Supplements Doc, is it good for my liver? Postgraduate Course: Challenges in Management of Common Liver Diseases 188 1 o Chief Complaint A 45 year old male
More informationLiver injury is a potential complication of many different
LIVER INJURY/REGENERATION Oral Medications with Significant Hepatic Metabolism at Higher Risk for Hepatic Adverse Events Craig Lammert, 1 Einar Bjornsson, 2 Anna Niklasson, 2 and Naga Chalasani 3,4 Reactive
More informationDrug-induced liver injury (DILI)
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2012 Drug-induced liver injury (DILI) Russmann, Stefan; Kullak-Ublick, Gerd
More informationDrug-induced liver injury (DILI) presents a
REVIEW HEPATOLOGY COMMUNICATIONS, VOL. 1, NO. 8, 2017 Drug-Induced Cholestasis Vinay Sundaram 1 and Einar S. Bj ornsson 2,3 Cholestatic drug-induced liver injury (DILI) can be a diagnostic challenge due
More informationTerbinafine hepatotoxicity. A case report and review of literature
Annals of Hepatology 2003; 2(1): January-March: 47-51 Case Report Annals of Hepatology Terbinafine hepatotoxicity. A case report and review of literature Alfonso Javier Zapata Garrido, 1 Alberto Casillas
More informationTraditional Chinese Medicine and Herb-induced Liver Injury: Comparison with Drug-induced Liver Injury
Review Article Traditional Chinese Medicine and Herb-induced Liver Injury: Comparison with Drug-induced Liver Injury Jing Jing 1,2 and Rolf Teschke* 3 1 Medical School of Chinese PLA, Beijing, China; 2
More informationDANTROLENE SODIUM IS a muscle relaxant that acts
ORIGINAL ARTICLE Safety of Low-Dose Oral Dantrolene Sodium on Hepatic Function Jung Yoon Kim, MD, Sewoong Chun, MD, Moon Suk Bang, MD, PhD, Hyung-Ik Shin, MD, PhD, Shi-Uk Lee, MD, PhD ABSTRACT. Kim JY,
More informationHHS Public Access Author manuscript Clin Gastroenterol Hepatol. Author manuscript; available in PMC 2016 February 01.
Clinical and Histological Features of Azithromycin-Induced Liver Injury Melissa A. Martinez 1, Raj Vuppalanchi 1, Robert J. Fontana 2, Andrew Stolz 3, David E. Kleiner 4, Paul H. Hayashi 5, Jiezhun Gu
More informationx B versus x ULN for Assessing Drug Effects
x B versus x ULN for Assessing Drug Effects Leonard B. Seeff, M.D. The Hill Group and the U.S. Food and Drug Administration Detecting and Evaluating Drug-Induced Liver Injury and Dysfunction University
More informationFebruary 8, World Journal of Gastroenterology. Re: ESPS Manuscript No Dear Dr. Qi:
February 8, 2017 World Journal of Gastroenterology Re: ESPS Manuscript No. 32025 Dear Dr. Qi: My co-authors and I respectfully submit the accompanying revised manuscript, Early hepatitis B viral DNA clearance
More informationWilliam M. Lee, MD. Aim: Discuss Clinical Trends in DILI and Acetaminophen Liver Injury
Drug-Induced Liver Injury (DILI) including Acetaminophen (APAP) 2014: Practical Tips William M. Lee, MD Clinical Professor Department of Internal Medicine Division of Gastroenterology, Hepatology & Nutrition
More informationAim: Discuss Clinical Trends in DILI and Acetaminophen Liver Injury
Drug-Induced Liver Injury (DILI) including Acetaminophen (APAP) 2014: Practical Tips DILI 2014: Aims/Topics Aim: Discuss Clinical Trends in DILI and Acetaminophen Liver Injury William M. Lee, MD Clinical
More informationAcute Liver Failure in the USA 2011 Evaluation of diagnostic criteria to approach DILI causality
Acute Liver Failure in the USA 2011 Evaluation of diagnostic criteria to approach DILI causality William M. Lee, MD Professor of Internal Medicine Meredith Mosle Chair in Liver Diseases UT Southwestern
More informationValidity of diagnostic codes and laboratory measurements to identify patients with idiopathic acute liver injury in a hospital database
pharmacoepidemiology and drug safety 2016; 25(Suppl. 1): 21 28 Published online 5 July 2015 in Wiley Online Library (wileyonlinelibrary.com).3824 ORIGINAL REPORT Validity of diagnostic codes and laboratory
More informationAnnouncing SIBO Testing Updates for February 2018
Announcing SIBO Testing Updates for February 208 Dear Valued Client, In the spirit of continuous improvement and updating our testing services with the most current science and research, BioHealth is aligning
More informationElevation of Serum Cytokines Preceding Elevation of Liver Enzymes in a Case of Drug-Induced Liver Injury
1 Elevation of Serum Cytokines Preceding Elevation of Liver Enzymes in a Case of Drug-Induced Liver Injury Keisuke Kakisaka 1)2) Yasuhiro Takikawa 2) 1) Department of Gastroenterology, Kazuno Kosei Hospital,
More informationDrug Induced Liver Injury (DILI) Sumita Verma Senior Lecturer Medicine, Hon Consultant Hepatologist Brighton and Sussex Medical School
Drug Induced Liver Injury (DILI) Sumita Verma Senior Lecturer Medicine, Hon Consultant Hepatologist Brighton and Sussex Medical School Disclosures None pertaining to current talk Research grants from Gilead,
More informationDisclosure. Evaluation of Abnormal Hepatic Enzymes
Evaluation of Abnormal Hepatic Enzymes Bruce D. Askey, MS, ANP-BC Associate Lecturer North Andover, MA Adult Nurse Practitioner Dept. of Hepatology/Gastroenterology Guthrie Clinic Sayre, Pa Disclosure
More informationCase Report Diphenhydramine as a Cause of Drug-Induced Liver Injury
Hindawi Case Reports in Hepatology Volume 217, Article ID 3864236, 4 pages https://doi.org/1.1155/217/3864236 Case Report Diphenhydramine as a Cause of Drug-Induced Liver Injury Yunseok Namn, 1 Yecheskel
More information06 June 2017 DILI Conference XVII FDA/AASLD/Critical Path Institute
1 DRUG-INDUCED LIVER INJURY How the clinical signature impacts benefits & risks June 6, 2017 Mark Avigan, MD CM Associate Director for Critical Path Initiatives Office of Pharmacovigilance & Epidemiology
More informationIN THE NAME OF GOD. D r. MANIJE DEZFULI AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL INFECTIOUS DISEASES SPECIALIST
IN THE NAME OF GOD AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL D r. MANIJE DEZFULI INFECTIOUS DISEASES SPECIALIST Acute Viral Hepatitis The Anatomy of the Liver Hepatic Physiology Liver: Largest solid organ
More informationDrug-Induced Liver Injury and Individual Cell Models
Dealing with DILI in Drug Development Dig Dis 2015;33:486 491 Drug-Induced Liver Injury and Individual Cell Models Andreas Benesic a, b Alexander L. Gerbes a a Liver Center Munich, Department of Medicine
More informationDILI PATHOLOGY. PHILIP KAYE November 2017 BSG Pathology Winter Meeting
DILI PATHOLOGY PHILIP KAYE November 2017 BSG Pathology Winter Meeting General Mechanisms Role of Liver Biopsy Outline Kleiner Categories Pathology! Differentials Severity Finally Drugs/Toxins may cause
More informationSUISSE ADPKD Cohort Treatment and Outcomes with Tolvaptan, first in class Vasopressin V2 Antagonist. Hirslanden, 22 March 2018 Stefan Russmann
SUISSE ADPKD Cohort Treatment and Outcomes with Tolvaptan, first in class Vasopressin V2 Antagonist Hirslanden, 22 March 2018 Stefan Russmann 4 th of July 2004 Database development with outcomes and safety
More informationVeterans Health Administration Lung Cancer Screening Demonstration Project: Results & Lessons Learned
Veterans Health Administration Lung Cancer Screening Demonstration Project: Results & Lessons Learned Jane Kim, MD, MPH Acting Chief Consultant for Preventive Medicine National Center for Health Promotion
More informationDrug Induced Liver Injury: Review with a Focus on Genetic Factors, Tissue Diagnosis, and Treatment Options
Drug Induced Liver Injury: Review with a Focus on Genetic Factors, Tissue Diagnosis, and Treatment Options The Harvard community has made this article openly available. Please share how this access benefits
More informationSpeaker Notes: Qualitative Comparative Analysis (QCA) in Implementation Studies
Speaker Notes: Qualitative Comparative Analysis (QCA) in Implementation Studies PART 1: OVERVIEW Slide 1: Overview Welcome to Qualitative Comparative Analysis in Implementation Studies. This narrated powerpoint
More informationKynamro. Kynamro (mipomersen) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.02 Subject: Kynamro Page: 1 of 5 Last Review Date: December 2, 2016 Kynamro Description Kynamro (mipomersen)
More informationCase Definition and Phenotype Standardization in Drug-Induced Liver Injury
nature publishing group state Case Definition and Phenotype Standardization in Drug-Induced Liver Injury GP Aithal 1, PB Watkins 2, RJ Andrade 3,4, D Larrey 5, M Molokhia 6, H Takikawa 7, CM Hunt 8, RA
More informationresearch methods & reporting
1 Centre for Medical Statistics and Health Evaluation, University of Liverpool, Liverpool L69 3GS 2 Centre for Statistics in Medicine, University of Oxford, Oxford OX2 6UD 3 Population, Community and Behavioural
More informationARQ 087 Overview. FGFR Inhibitor. March 2017
ARQ 087 Overview FGFR Inhibitor March 2017 Safe Harbor This presentation and other statements by ArQule contain forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationDrug-Induced Liver Injury in HIV-Infected Patients with Opportunistic Infections: Causes, Clinical Features and Predictors in Chinese Patients
l Journal of AIDS & Clinica ISSN: 2155-6113 Research Journal of AIDS & Clinical Research Xiao et al., 2016, 7:7 DOI: 10.4172/2155-6113.1000591 Research Article Open Access Drug-Induced Liver Injury in
More informationIntrinsic vs. Idiosyncratic DILI
Idiosyncratic Drug Induced Liver Injury Naga Chalasani, MD, FACG Professor & Director Division of GI and Hepatology Indiana University School of Medicine Clarian/IU Digestive Diseases Center ACG PG Course
More informationManagement of Acute HCV Infection
Management of Acute HCV Infection This section provides guidance on the diagnosis and medical management of acute HCV infection, which is defined as presenting within 6 months of the exposure. During this
More informationSuspected Isoflurane Induced Hepatitis from Cross Sensitivity in a Post Transplant for Fulminant Hepatitis from Halothane.
ISPUB.COM The Internet Journal of Anesthesiology Volume 25 Number 1 Suspected Isoflurane Induced Hepatitis from Cross Sensitivity in a Post Transplant for Fulminant Hepatitis from Halothane. V Sampathi,
More informationActive TB drug-safety management & monitoring
Active TB drug-safety management & monitoring Global TB Programme, WHO, Switzerland 6 August 2015 Pharmacovigilance: definition of science and activities relating to the detection, assessment, understanding
More informationInitially purported hepatotoxicity by Pelargonium sidoides: the dilemma of pharmacovigilance and proposals for improvement
ORIGINAL ARTICLE July-August, Vol. 11 No.4, 2012: 500-512 Initially purported hepatotoxicity by Pelargonium sidoides: the dilemma of pharmacovigilance and proposals for improvement Rolf Teschke,* Christian
More informationMANAGEMENT OF DILI in TB/HIV coinfected patients. Chimoio 31 August 2017 by Dr Ndiviwe Mphothulo
MANAGEMENT OF DILI in TB/HIV coinfected patients Chimoio 31 August 2017 by Dr Ndiviwe Mphothulo ANTI-TB drugs Groups Drugs Group 1: First-line oral drugs Ethambutol (Emb) Pyrazinamide(PZA) Isoniazid (INH)
More informationOverview of PSC Making the Diagnosis
Overview of PSC Making the Diagnosis Tamar Taddei, MD Assistant Professor of Medicine Yale University School of Medicine Overview Definition Epidemiology Diagnosis Modes of presentation Associated diseases
More informationWho to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat
Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor
More informationThe liver and skin are two of the commonest
AMERICAN ASSOCIATION FOR THE STUDY OFLIVERD I S E ASES HEPATOLOGY, VOL. 63, NO. 3, 2016 LIVER INJURY/REGENERATION Drug-Induced Liver Injury Associated With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis:
More informationCancer Control Council Evaluation and Monitoring Framework
Cancer Control Council Evaluation and Monitoring Framework Table of contents 1. Purpose...1 2. Background...1 3. Clarification of key tasks...2 4. International evaluation and monitoring frameworks...3
More informationThe predictive value of serum alanine transaminase activity on first presentation to hospital in patients with paracetamol poisoning
The predictive value of serum alanine transaminase activity on first presentation to hospital in patients with paracetamol poisoning Khalid Al-Hourani, Rachel Mansi, Janice Pettie, Margaret Dow, Nick Bateman
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #400 (NQF 3059): One-Time Screening for Hepatitis C Virus (HCV) for Patients at Risk National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY
More informationAdvanced Skin Cancer Screenings. Research Collaboration
Advanced Skin Cancer Screenings Research Collaboration Collaboration Opportunities April 2018 Advanced Skin Cancer Screenings Advanced Skin Cancer Screenings (ASCS) are the focus of a research collaboration
More informationMoving from Preclinical to Clinical Studies
Global Product Patient Safety Biomarkers for DILI: Moving from Preclinical to Clinical Studies Arie Regev, M.D. Global Patient Safety Eli Lilly and Company Indianapolis, IN New IDILI Biomarkers in the
More informationDrug-Induced Liver Injury
Drug-Induced Liver Injury Nizar A. Mukhtar, MD Swedish Organ Transplant & Liver Center 2017 Spring Hepatology Update April 29, 2017 1 DILI - Outline Definition/Epidemiology Pathogenesis Risk Factors Clinical
More informationGoing Beyond the Didactic Lecture & Using Innovative Methods and Technologies to Enhance the Learning Experience. Thursday, October 16, 2014
Are You Game? Going Beyond the Didactic Lecture & Using Innovative Methods and Technologies to Enhance the Learning Experience Thursday, October 16, 2014 Marilyn Peterson, MA, CCMEP, FACEHP Jessica Stewart,
More informationThe detection and management of pain in patients with dementia in acute care settings: development of a decision tool: Research protocol.
The detection and management of pain in patients with dementia in acute care settings: development of a decision tool: Research protocol. Aims and Objectives of the overall study The aim of this study
More informationA focus on epidemiology of drug-induced liver injury: analysis of a prospective cohort
European Review for Medical and Pharmacological Sciences 2017; 21 (1 Suppl): 112-121 A focus on epidemiology of drug-induced liver injury: analysis of a prospective cohort A. LICATA, M.G. MINISSALE, V.
More informationRecent Advances in Hepatotoxicity of Non Steroidal Anti-inflammatory Drugs
VIEWPINT March-April, Vol. 17 No. 2, 2018: 187-191 187 The fficial Journal of the Mexican Association of Hepatology, the Latin-American Association for Study of the Liver and the Canadian Association for
More informationHow to use statins in patients with chronic liver disease
REVIEW CME CREDIT MARK W. RUSSO, MD Center for the Study of Hepatitis C, Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, NY IRA M. JACOBSON, MD Center for the Study
More informationDrug Induced Liver Disease Role of the Pathologist. Disclosure. DILI can never be excluded. Romil Saxena, MD. Dr. Saxena has nothing to Disclose
Drug Induced Liver Disease Role of the Pathologist Romil Saxena, MD Disclosure Dr. Saxena has nothing to Disclose DILI can never be excluded #1 DILI has no specific pattern of injury it can mimic any and
More informationSultan Qaboos University Hospital Medicines Information Course. Assessment
Sultan Qaboos University Hospital Medicines Information Course Assessment Overview. As the course is delivered at three levels; Basic (BL), Intermediate (IL) and Advanced (AL) there are also three levels
More informationAmmonia level at admission predicts in-hospital mortality for patients with alcoholic hepatitis
Gastroenterology Report, 5(3), 2017, 232 236 doi: 10.1093/gastro/gow010 Advance Access Publication Date: 1 May 2016 Original article ORIGINAL ARTICLE Ammonia level at admission predicts in-hospital mortality
More informationRecent Status of Drug-induced Liver Injury and Its Problems in Japan
Research and Reviews Recent Status of Drug-induced Liver Injury and Its Problems in Japan JMAJ 53(4): 243 247, 2010 Hajime TAKIKAWA* 1 Abstract Adverse drug reactions are becoming a social issue in recent
More informationInvestigation of Ocular Melanoma Incidence, an Aggressive Form of Rare Tumor
Investigation of Ocular Melanoma Incidence, an Aggressive Form of Rare Tumor Chandrika Rao, PhD., Director, North Carolina Central Cancer Registry (NAACCR Communications Committee, NAACCR Narrative Production
More informationWe are inviting you to participate in a research study/project that has two components.
Dear TEACCH Client: One of the missions of the TEACCH Autism Program is to support research on the treatment and cause of autism and related disorders. Therefore, we are enclosing information on research
More informationThis memo includes background of the project, the major themes within the comments, and specific issues that require further CSAC/HITAC action.
TO: FR: RE: Consensus Standards Approval Committee (CSAC) Health IT Advisory Committee (HITAC) Helen Burstin, Karen Pace, and Christopher Millet Comments Received on Draft Report: Review and Update of
More informationThe diagnosis of Chronic Pancreatitis
The diagnosis of Chronic Pancreatitis 1. Background The diagnosis of chronic pancreatitis (CP) is challenging. Chronic pancreatitis is a disease process consisting of: fibrosis of the pancreas (potentially
More information